calendar
346 catalysts · 4,110 phase readout · 2,205 8k filing · 281 earnings · 172 phase 2 completion · 110 drug shortage · 73 phase 1 completion
next 91 dayslessmore
MonWedFri
346 catalysts · 4,110 phase readout · 2,205 8k filing · 281 earnings · 172 phase 2 completion · 110 drug shortage · 73 phase 1 completion
Ice Cream
Sponsor: MANKIND PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: RK PHARMA. Form: TABLET. Route: ORAL
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
Canine milk replacer
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Angio Packs (AMS6908E and AMS6908F)
Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Vanilla Bourbon Trail Mix
Anticipated earnings call for ACME UNITED CORP ($ACU).
Anticipated earnings call for Sanofi ($SNY).
Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus
Therapy area: Immunology. Indication: Liver Transplant Rejection
Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas
Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor
Therapy area: Undisclosed. Indication: Unspecified
Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders
Therapy area: Central Nervous System. Indication: Schizophrenia, Unspecified Neurologic Disorders
Therapy area: Immunology. Indication: Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
Therapy area: Immunology. Indication: Autoimmune Disorders, Diffuse Cutaneous Systemic Sclerosis, Systemic Sclerosis (Scleroderma)
Therapy area: Metabolic Disorders, Musculoskeletal Disorders. Indication: Gouty Arthritis (Gout), Hyperuricemia
Therapy area: Dermatology. Indication: Burns
Therapy area: Metabolic Disorders. Indication: Obesity, Overweight
Therapy area: Central Nervous System. Indication: Parkinson's Disease
Anticipated earnings call for NOVARTIS AG ($NVS).
Anticipated earnings call for INCYTE CORP ($INCY).
Anticipated earnings call for ECOLAB INC. ($ECL).
Anticipated earnings call for Orion Group Holdings Inc ($ORN).
Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer
Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)
Therapy area: Metabolic Disorders. Indication: Phenylketonuria (PKU)
Therapy area: Cardiovascular. Indication: Ischemic Stroke
Anticipated earnings call for AbbVie Inc. ($ABBV).
Anticipated earnings call for ASTRAZENECA PLC ($AZN).
Anticipated earnings call for GSK plc ($GSK).